Belousova E D, Shulyakova I V, Ohapkina T G
Veltischev Research and Clincal Institute of Pediatric, Moscow, Russia, Pirogov Russian National Research Medical University, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(9. Vyp. 2):61-66. doi: 10.17116/jnevro20161169261-66.
West syndrome is one of the most well-known epileptic encephalopathies, a catastrophic epilepsy syndrome with onset in the first year of life. Prognosis of this condition depends on the etiology and adequate treatment. The authors review the hormonal treatment of West syndrome. Adrenocorticotrophic hormone (ACTH) is used in USA and its synthetic analogue tetracosactide is used in Europe. Both of the drugs are not registered in the Russian Federation. The data on the efficacy of corticosteroids, including prednisolone, are contradictory. Recent results have demonstrated the high efficacy of prednisolone in the treatment of West syndrome. The authors discuss different aspects of hormonal treatment of West syndrome: possible mechanisms, choice of medication, hormone doses, its duration, efficacy ant tolerability.
韦斯特综合征是最著名的癫痫性脑病之一，是一种在生命第一年发病的灾难性癫痫综合征。这种疾病的预后取决于病因和适当的治疗。作者回顾了韦斯特综合征的激素治疗。促肾上腺皮质激素（ACTH）在美国使用，其合成类似物替可克肽在欧洲使用。这两种药物在俄罗斯联邦均未注册。关于包括泼尼松龙在内的皮质类固醇疗效的数据相互矛盾。最近的结果表明泼尼松龙在治疗韦斯特综合征方面具有高效性。作者讨论了韦斯特综合征激素治疗的不同方面：可能的机制、药物选择、激素剂量、治疗持续时间、疗效和耐受性。
